Refractory Angina Treatment Market Size
Market Size in USD Mn
CAGR5.6%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 5.6% |
| Market Concentration | Medium |
| Major Players | Imbria Pharmaceuticals, Angionetic Inc, Xylocor Therapeutics Inc, Caladrius Biosciences Inc and Among Others |
please let us know !
Refractory Angina Treatment Market Analysis
The Global Refractory Angina Treatment Market is estimated to be valued at USD 211.3 Mn in 2025 and is expected to reach USD 309.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032. Refractory angina refers to a rare form of angina that does not respond to conventional treatments such as medication or surgery. This condition severely impacts the quality of life of those affected.
The market is expected to witness steady growth over the forecast period driven by the increasing prevalence of cardiovascular diseases along with limited treatment options for refractory angina. Various pipeline drugs and refractory angina treatment devices in clinical trials can potentially drive the market if approved. However, lack of awareness about refractory angina and high treatment costs remains major challenges to adoption.